Clinical trials: Schizophrenic Patients
Schizophrenia
A Switch Study of BMS-337039 in Schizophrenic Out-patients
The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general…
- Trial name
- NCT00232687
- Testing
- Aripiprazole
- Where
- 72 sites in Austria, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Depression
Quetiapine Extended Release Depression Symptoms
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
- Trial name
- ExAttitude (NCT00640562)
- Testing
- Quetiapine Extended Release, Risperidone
- Where
- 21 sites in Italy
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Schizophrenia
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms.
- Trial name
- NCT00159757
- Testing
- ziprazidone
- Where
- 8 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
- Trial name
- NCT00396214
- Testing
- Bifeprunox, Quetiapine
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 83 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia
Epidemiology of Schizophrenia in Bulgaria
The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of: Patient characteristics.
- Trial name
- NCT00984373
- Where
- 7 sites in Bulgaria
- Volunteers
- 440 people
- Sponsor
- AstraZeneca
Schizophrenia
Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
Brief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public. Limit: 5000 characters.
- Trial name
- NCT05563818
- Testing
- WinterLight Mobile Phone Speech Analysis
- Where
- 4 sites in Algeria, Egypt and 2 more
- Volunteers
- 57 people
- Sponsor
- Hikma Pharmaceuticals LLC
Schizophrenia
Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
- Trial name
- NCT00300963
- Testing
- Talnetant
- Where
- 20 sites in United States
- Volunteers
- 275 people
- Sponsor
- GlaxoSmithKline
Schizophrenic Disorder
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia.
- Trial name
- NCT00206115
- Testing
- Seroquel Sustained Release (SR), Seroquel Immediate Release (IR)
- Where
- 31 sites in Bulgaria, Greece and 6 more
- Volunteers
- 535 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorder
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with a fixed 10-mg dose of a standard antipsychotic, haloperidol, in patients with…
- Trial name
- NCT00249119
- Testing
- risperidone
- Volunteers
- 1,579 people
- Sponsor
- Janssen, LP
Schizophrenia
A Study in Schizophrenic Patients
This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.
- Trial name
- NCT01125358
- Testing
- LY2140023
- Where
- 22 sites in Japan, South Korea and 1 more
- Volunteers
- 82 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Schizophrenia Trial of Aripiprazole
Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).
- Trial name
- NCT00237913
- Testing
- Aripiprazole, Olanzapine or Quetiapine or Risperidone
- Where
- 33 sites in Austria, Czechia and 7 more
- Volunteers
- 700 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
The purpose of this study is to evaluate the effect of single doses of NSA-789 on the P50 component of the auditory evoked potentials and to assess the safety, tolerability and the concentration of NSA-789 in the blood, in…
- Trial name
- NCT00781794
- Testing
- NSA-789 at 2 different doses
- Where
- 3 sites in United States, France
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Effect on Cognitive Function of a Treatment With Aripiprazole
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
- Trial name
- NCT00329810
- Testing
- Aripiprazole
- Volunteers
- 500 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.